We value your privacy

This website or its third-party tools process personal data. You can opt out of the sale of your personal information by clicking on the “Do Not Sell or Share My Personal Information” link.

Powered by

Reyvow

ACNU Feasibility

View full report
GoodReyvow is an oral tablet for migraine with moderate CNS side effects, interaction risks, and special population cautions. It requires single-dose adherence, some monitoring for CNS effects, and has low misuse potential, aligning with FDA ACNU safety and usability considerations.

ACNU Feasibility Scorecard

Chart with 11 data points.
Reyvow
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying ← Lower is Better!. Data ranges from 1 to 6.
End of interactive chart.